BSC

Blockchain Market - Global Forecast to 2030: Market to Grow at a CAGR of 67.7% to Reach a Value of Over $400 Billion - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 28, 2023
Technology, Blockchain, Bitcoin, Polygon, Sustainable Energy Utility, Organization, Certification, Patient, Entertainment, BSC, Terra, Growth, BFSI, SME, Cryptocurrency, Ethereum, Geography

The global blockchain market is projected to reach $403.36 billion by 2030, at a CAGR of 67.7% from 2023 to 2030.

Key Points: 
  • The global blockchain market is projected to reach $403.36 billion by 2030, at a CAGR of 67.7% from 2023 to 2030.
  • One of the most well-known applications of blockchain technology is Bitcoin, a decentralized digital currency that operates on a blockchain network.
  • In addition, regulatory uncertainty and lack of interoperability between blockchain ecosystems are major challenges to the growth of this market.
  • Who are the local emerging players in the global blockchain market, and how do they compete with other players?

Sori Finance (SORI) Is Now Available for Trading on LBank Exchange

Retrieved on: 
Saturday, June 24, 2023
NFT, Non-fungible token, Decentralized finance, Android, IOS, Swap, BSC, Growth, Ecosystem, Cryptocurrency

Road Town, British Virgin Islands--(Newsfile Corp. - June 24, 2023) - LBank Exchange, a global digital asset trading platform, listed Sori Finance (SORI) on June 22, 2023.

Key Points: 
  • Road Town, British Virgin Islands--(Newsfile Corp. - June 24, 2023) - LBank Exchange, a global digital asset trading platform, listed Sori Finance (SORI) on June 22, 2023.
  • For all users of LBank Exchange, the SORI/USDT trading pair is now officially available for trading.
  • Sori Finance (SORI) is a community-focused DeFi project that made a fair launch of Sori (SORI) cryptocurrency.
  • LBank Exchange is thrilled to announce the listing of Sori Finance (SORI), a community-focused DeFi project that made a fair launch of Sori (SORI) cryptocurrency.

Bitget Becomes the First Major Exchange to Support USDT on Kava Blockchain

Retrieved on: 
Friday, June 23, 2023
Tether, Ethereum, Cosmos, ETH, SOL, HT, MATIC, Kava, TRX, USDT, BSC, Ecosystem, Cryptocurrency, Optimism, Bitget

Tether, the company operating the blockchain-enabled platform tether.to, has chosen Kava, a layer-1 blockchain renowned for its scalability and speed, as the latest platform to launch USDT.

Key Points: 
  • Tether, the company operating the blockchain-enabled platform tether.to, has chosen Kava, a layer-1 blockchain renowned for its scalability and speed, as the latest platform to launch USDT.
  • "We are thrilled to support the integration of USDT on the Kava blockchain, granting our users access to the world's most trusted stablecoin," stated Gracy Chen, Managing Director of Bitget.
  • The support for USDT Tether on Kava adds another layer of stability and accessibility to Bitget's trading ecosystem, enhancing the overall trading experience for its users.
  • For further information and updates on Bitget's support for USDT Tether on Kava and related developments, please visit the official announcement .

Bitget Becomes the First Major Exchange to Support USDT on Kava Blockchain

Retrieved on: 
Friday, June 23, 2023
Tether, Ethereum, Cosmos, ETH, SOL, HT, MATIC, Kava, TRX, USDT, BSC, Ecosystem, Cryptocurrency, Optimism, Bitget

Tether, the company operating the blockchain-enabled platform tether.to, has chosen Kava, a layer-1 blockchain renowned for its scalability and speed, as the latest platform to launch USDT.

Key Points: 
  • Tether, the company operating the blockchain-enabled platform tether.to, has chosen Kava, a layer-1 blockchain renowned for its scalability and speed, as the latest platform to launch USDT.
  • "We are thrilled to support the integration of USDT on the Kava blockchain, granting our users access to the world's most trusted stablecoin," stated Gracy Chen, Managing Director of Bitget.
  • The support for USDT Tether on Kava adds another layer of stability and accessibility to Bitget's trading ecosystem, enhancing the overall trading experience for its users.
  • For further information and updates on Bitget's support for USDT Tether on Kava and related developments, please visit the official announcement .

Palmswap Secures Partnership with Gotbit for the Palmswap Liquidity Event

Retrieved on: 
Wednesday, June 21, 2023
PALM, Partnership, Touchpad, Risk management, Binance, CEX, Launch, FCFS, PLP, USDT, BSC, Growth, DEX, APR, Cryptocurrency, Online shopping

An undisclosed amount will be allocated from Gotbit, through the minting and auto-staking of the Palmswap Liquidity Provider (PLP) token during the Launch Event beginning June 27.

Key Points: 
  • An undisclosed amount will be allocated from Gotbit, through the minting and auto-staking of the Palmswap Liquidity Provider (PLP) token during the Launch Event beginning June 27.
  • Gotbit Hedge Fund is a performance-focused crypto market maker with a platform-based service and utility integration approach.
  • According to Palmswap’s CPO Bernd Stöckl: “Our upcoming liquidity event will usher in a new era of fast, efficient, and user-friendly decentralized trading.
  • With the deep liquidity being provided via Gotbit and the active participation and growth of the Palmswap user base, Palmswap – specifically, Palmswap v2, the new iteration of the Palmswap decentralized leveraged trading platform – is perfectly positioned to sustain growth and activity by a new wave of Web3 participants.

BetFury Launches Crypto Rush Event, New Era of BFG Starting

Retrieved on: 
Wednesday, June 21, 2023
Crypto, Monte Carlo algorithm, Friends, ETH, CertiK, Staking, Reward, IGaming Business, TRX, USDT, BFG, Gold, BSC, Madison Square Garden Gold Ticket Award, BTC, BNB, APY, Cryptocurrency, Sport, Mining

NEW YORK, NY, June 21, 2023 (GLOBE NEWSWIRE) -- BetFury is proud to announce the launch of its Crypto Rush event which will start a new era of BFG.

Key Points: 
  • NEW YORK, NY, June 21, 2023 (GLOBE NEWSWIRE) -- BetFury is proud to announce the launch of its Crypto Rush event which will start a new era of BFG.
  • Hence, in honor of the end of BFG Mining, BetFury is holding a grand Crypto Rush event with the $800,000 prize pool.
  • Therefore, along with thematic entertainment, Crypto Rush allows users to get a lot of BFG tokens.
  • Thus, investing in BFG and participating in Crypto Rush is a great way to make money from tokens in the future.

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

Retrieved on: 
Friday, June 16, 2023
Priority review, CRC, Progression-free survival, TAK, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, NDA, Oncology, Marketing, EMA, HKEX, Patient, PMDA, BSC, MAA, European Society of Gynaecological Oncology, Phase, Lancet, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, Pharmaceutical industry, Takeda

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. and OSAKA, Japan and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) and Takeda (TSE:4502, NYSE:TAK) today announced that results of the Phase III FRESCO-2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer (“CRC”) were published in The Lancet.  

Key Points: 
  • The publication provides details of the FRESCO-2 study results as of June 24, 2022.
  • Summary results from this cut-off date were presented on September 12, 2022, at the European Society for Medical Oncology Congress 2022 (“ESMO22”).
  • Fruquintinib is a highly selective and potent inhibitor of vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3.
  • In March 2023, HUTCHMED and Takeda closed an exclusive license agreement to further the global development, commercialization and manufacture of fruquintinib outside of China.

BNB Chain's Perpetual Platform MEKE to Make Foray into Cryptocurrency Derivative Market

Retrieved on: 
Thursday, June 15, 2023
CertiK, Binance, BSC, USDT, Chain-link fencing, Map, Algorithm, MetaMask, Video game, Cryptocurrency

The cryptocurrency trading market can be broadly divided into two categories: spot trading and derivative trading.

Key Points: 
  • The cryptocurrency trading market can be broadly divided into two categories: spot trading and derivative trading.
  • MEKE , an on-chain perpetual protocol platform developed by a US technology team, will soon be launched, preparing to make a foray into the cryptocurrency derivative market capable of generating hundreds of millions of dollars of profit per day.
  • In contrast to the spot trading market, cryptocurrency derivative trading boasts a greater size and is still in the process of maturing.
  • As such, there is a pressing demand among traders for a decentralized cryptocurrency derivative trading platform that offers security, transparency, and user-friendliness.

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Retrieved on: 
Thursday, June 15, 2023
Priority review, CRC, Progression-free survival, Marketing, TAK, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, JAMA, NDA, Prescription Drug User Fee Act, EMA, American Medical Association, VEGF, HKEX, Journal, Patient, Physician, PMDA, PDUFA, BSC, MAA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Takeda

OSAKA, Japan and CAMBRIDGE, Mass. and HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Takeda (TSE:4502/​NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“HUTCHMED”) today announced that the European Medicines Agency (“EMA”) has validated and accepted for regulatory review the marketing authorization application (“MAA”) for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (“CRC”). If approved, fruquintinib will be the first and only highly selective inhibitor of all three VEGF receptors approved in the E.U. for previously treated metastatic CRC.1,2

Key Points: 
  • Placebo plus BSC for Adult Patients with Previously Treated Metastatic Colorectal Cancer —
    OSAKA, Japan and CAMBRIDGE, Mass.
  • If approved, fruquintinib will be the first and only highly selective inhibitor of all three VEGF receptors approved in the E.U.
  • for previously treated metastatic CRC.1,2
    “European patients with metastatic colorectal cancer have not benefitted from a treatment advancement in over a decade,” said Awny Farajallah, M.D., head of Global Medical Affairs Oncology at Takeda.
  • who find treatment options to be limited for previously treated metastatic colorectal cancer,” said Dr. Michael Shi, Head of R&D and Chief Medical Officer, HUTCHMED.

Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet

Retrieved on: 
Friday, June 16, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Priority review, CRC, Progression-free survival, TAK, European Medicines Agency, New Drug Application, OS, NDA, Medicines and Healthcare products Regulatory Agency, PFS, Marketing, EMA, Patient, PMDA, VEGFR, BSC, MAA, European Society of Gynaecological Oncology, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HCM, Food, Pharmaceutical industry, Takeda, Lancet

Takeda ( TSE:4502/NYSE:TAK ) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) ( HUTCHMED ) today announced that results of the Phase 3 FRESCO2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer (CRC) were published in The Lancet.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) ( HUTCHMED ) today announced that results of the Phase 3 FRESCO2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer (CRC) were published in The Lancet.
  • The publication provides details of the FRESCO-2 study results as of June 24, 2022.
  • Summary results from this cut-off date were presented on September 12, 2022, at the European Society for Medical Oncology Congress 2022 (ESMO22).
  • In March 2023, HUTCHMED and Takeda closed an exclusive license agreement to further the global development, commercialization and manufacture of fruquintinib outside of China.